Veterinary Medicines

VANGUARD 7 sospensione iniettabile per cani

Authorised
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parainfluenza virus, strain NL-CPI-5, Live
  • Canine parvovirus, strain NL-35-D, Live
  • Canine distemper virus, strain N-CDV, Live
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
Download as PDF

Product identification

Medicine name:
VANGUARD 7 sospensione iniettabile per cani
Active substance:
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parainfluenza virus, strain NL-CPI-5, Live
  • Canine parvovirus, strain NL-35-D, Live
  • Canine distemper virus, strain N-CDV, Live
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
Target species:
  • Dog
Route of administration:
  • Intramuscular use
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine adenovirus 2, strain Manhattan, Live
    3.20
    log10 cell culture infective dose 50
    /
    1.00
    millilitre(s)
  • Canine parainfluenza virus, strain NL-CPI-5, Live
    6.00
    log10 cell culture infective dose 50
    /
    1.00
    millilitre(s)
  • Canine parvovirus, strain NL-35-D, Live
    7.00
    log10 cell culture infective dose 50
    /
    1.00
    millilitre(s)
  • Canine distemper virus, strain N-CDV, Live
    3.00
    log10 cell culture infective dose 50
    /
    1.00
    millilitre(s)
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
    463.00
    relative unit(s)
    /
    1.00
    millilitre(s)
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
    420.00
    relative unit(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Dog
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AI02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Italy
Available in:
  • Italy
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Zoetis Italia S.r.l
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Belgium
  • Haupt Pharma Latina S.r.l.
Responsible authority:
  • Ministry Of Health
Authorisation number:
This information is not available for this product.
Date of authorisation status change:

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Italian (PDF)
Published on: 23/03/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."